Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 9, 2026 · Filed Nov 12, 2026
An Alnylam Pharmaceuticals director paid $300K out of pocket for Alnylam Pharmaceuticals shares. 1 other person at Alnylam Pharmaceuticals bought some too, in the same month. It was the first purchase in over a year.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$299,526
Shares × reported transaction price
$100K–$500K
+7.9%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
None in 27 months of history
Confirmed open-market purchases by the same insider in the available history
2 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
11 days after results of Oct 29, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $156.61 on Nov 9, 2026, within 1% of its 52-week low, after a 39% drop over the previous 30 trading days
52-week range $155.94 (Nov 6, 2026) to $473.29 (Dec 3, 2025), 0% of the way up, from 250 adjusted closes. 30 trading days earlier: $255.36 on Sep 28, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
The first open-market purchase by any ALNY insider since Oct 2024. Amy W Schulman's first open-market purchase of ALNY in filings since 2006
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
Insider filing
Traded Nov 10 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Insider filing
Traded Nov 10 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Insider buying
Their first buy on recordTraded Nov 10 · filed 2 days later
An Alnylam Pharmaceuticals director paid $244K out of pocket for Alnylam Pharmaceuticals shares. 1 other person at Alnylam Pharmaceuticals bought some too, in the same month. It was the first purchase in over a year.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
